Bessemer Group
HBIO icon

Bessemer Group’s Harvard Bioscience HBIO Stock Holding History

Bessemer Group’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-31
Closed -$1K – 1635
2015
Q3 		$1K Buy
+31
New +$1.44K ﹤0.01% 1533

Other funds holding HBIO

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bessemer Group's HBIO Position: Q4 2015 in Review

Bessemer Group sold out of Harvard Bioscience (HBIO) in Q4 2015, closing a stake of 31 shares — an estimated $1K sold.

Bessemer Group first reported a position in HBIO in Q3 2015 and held it in 1 quarter. The position peaked at $1K in Q3 2015. 81 funds tracked by Wall St. Rank hold HBIO as of Q4 2015.

  • Bessemer Group reported no remaining Harvard Bioscience position as of Q4 2015 after selling out during the quarter.
  • Bessemer Group sold 31 Harvard Bioscience shares in Q4 2015, an estimated $1K.
  • Bessemer Group first reported a position in Harvard Bioscience in Q3 2015 and held it in 1 quarter.
  • Bessemer Group's Harvard Bioscience position peaked at $1K in Q3 2015.
  • 81 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2015.

Based on Bessemer Group's 13F filing for Q4 2015, filed 12 Feb 2016.